Malignant Ascites Clinical Trial
Official title:
Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks for up to six weeks, or a maximum of three treatments.
This protocol describes a pilot study to assess whether intraperitoneal Bevacizumab infusion is safe and improves the time to repeat paracentesis. In patients with non-draining malignant peritoneal effusion, published data suggests that the average time to repeat paracentesis in malignant ascites is 10-13 Days. The investigators' treatment will be considered potentially efficacious if the median time to repeat paracentesis is greater than 14 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06200376 -
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT04051112 -
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
|
Phase 1 | |
| Completed |
NCT00836654 -
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05501340 -
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03550560 -
EUS-Guided Drainage of Refractory Malignant Ascites
|
||
| Recruiting |
NCT04501744 -
A Study of M701 (EpCAM and CD3) in Malignant Ascites
|
Phase 1 | |
| Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
| Recruiting |
NCT05477927 -
Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT06266091 -
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
|
Phase 2 | |
| Withdrawn |
NCT04076566 -
Malignant Ascites Alfapump® Study
|
||
| Enrolling by invitation |
NCT01854866 -
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
|
Phase 2 | |
| Recruiting |
NCT03230708 -
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
|
Phase 1/Phase 2 | |
| Completed |
NCT01327235 -
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Completed |
NCT01532427 -
ALFApump System Post Marketing Surveillance Registry
|
||
| Completed |
NCT00326885 -
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT02530398 -
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
|
Phase 1 | |
| Withdrawn |
NCT00908219 -
A Study of Bevacizumab to Prevent Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT06016179 -
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT03736122 -
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
|
Phase 1/Phase 2 |